StreetInsider.com News Articles

Immunic to present MS drug data at Toronto conference

Wed, 07 Oct 2026 08:00:31 -0400

Immunic, Inc. (Nasdaq: IMUX) announced that four abstracts on its investigational drug vidofludimus calcium (IMU-838) have been accepted for presentation at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, scheduled for October 21-23, 2026, in Toronto, Canada.

The presentations cover long-term disability outcomes from the Phase 2 CALLIPER open-label extension trial in progressive multiple sclerosis (MS), preclinical neuronal survival data, Epstein-Barr virus-related immune activity and cognition, and a proposed bidirectional disability measurement endpoint.

Data from the CALLIPER open-label extension show that patients who received continuous vidofludimus calcium treatment maintained trends toward lower risk of 24-week confirmed disability worsening through extension week 48, with confirmed

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Wed, 07 Oct 2026 08:00:00 -0400

– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Novel Disability Measurement, and Nurr1-Mediated Neuronal Survival –

– New Phase 2 CALLIPER Open-Label Extension Data Show Disability Outcomes Favoring Continuous Vidofludimus Calcium Treatment Maintained Through Extension Week 48, With Low Treatment Discontinuation –

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Wed, 07 Oct 2026 08:00:00 -0400

Form S-8 IMMUNIC, INC.

Thu, 01 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261001/27135915.html

Form 4 IMMUNIC, INC. For: Sep 16 Filed by: Nagel Robert Thorvald

Fri, 18 Sep 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260918/27081577.html

Form 4 IMMUNIC, INC. For: Sep 16 Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 18 Sep 2026 19:46:00 -0400

si-local-file:///var/storage/secattach/20260918/27081531.html

Form 8-K IMMUNIC, INC. For: Sep 10

Fri, 11 Sep 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260911/27053723.html

Immunic (IMUX) Reiterated at Buy by Stifel Post R&D Event

Thu, 10 Sep 2026 07:40:28 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $25.00 price target on Immunic Inc. (NASDAQ: IMUX).

The analyst commented, "In their R&D Event, IMUX mgmt was joined by Drs Bar-Or (UPenn, CHOP) and Krieger (Mt Sinai) to discuss the MS landscape and the VidoCa program. Highlights include: (1) KOLs emphasis around the residual unmet need in MS, especially PIRA--which even high-efficacy therapies don't address, (2) new preclinical data supporting VidoCa's Nurr1 activator properties and the neuroprotective benefits of this target, (3) mgmt's confidence on the upcoming ph3 ENSURE-1/2 readouts based on the positive ph2 RRMS data, and (4) IMUX's claims

H.C. Wainwright Reiterates Buy Rating on Immunic Inc. (IMUX)

Thu, 10 Sep 2026 06:53:29 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $22.00 price target on Immunic Inc. (NASDAQ: IMUX).

The analyst commented: "The company hosted an R&D Day and KOL discussion focusing on lead oral candidate vidofludimus calcium as we get closer to the pivotal Phase 3 ENSURE-1 and ENSURE-2 trial topline in relapsing multiple sclerosis (RMS) patients anticipated by the end of 2026. We believe an important point was that despite several approved treatments including anti-CD20s and current oral RMS therapies targeting inflammation and relapses, drivers of progression include relapse-associated worsening (RAW), and progression independent of relapse activity (PIRA), and remain

Wedbush Starts Immunic Inc. (IMUX) at Outperform

Mon, 17 Aug 2026 07:06:16 -0400

(Updated - August 17, 2026 7:06 AM EDT)

Wedbush analyst Martin Fan initiates coverage on Immunic Inc. (NASDAQ: IMUX) with a Outperform rating and a price target of $45.00.

The analyst comments "IMUX is a clinical-stage biopharmaceutical company developing immune modulators for immunology and inflammation (I&I). Lead program vidofludimus calcium (IMU-838) is a dual-action selective DHODH inhibitor and Nurr1 activator in Phase 3 development for relapsing multiple sclerosis (RMS), with Phase 2 data also supporting activity in both relapsing and progressive forms of MS. Patient followup indicates high durability of response and an advantageous safety profile relative to other approved drug classes,

Wedbush Starts Immunic Inc. (IMUX) at Outperform

Mon, 17 Aug 2026 07:06:16 -0400

(Updated - August 17, 2026 7:06 AM EDT)

Wedbush analyst Martin Fan initiates coverage on Immunic Inc. (NASDAQ: IMUX) with a Outperform rating and a price target of $45.00.

Form SCHEDULE 13G IMMUNIC, INC. Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26932989.html

Form SCHEDULE 13G IMMUNIC, INC. Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26932989.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932177.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932177.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931172.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931172.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917376.html

Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917376.html

Form S-8 IMMUNIC, INC.

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912778.html

Form S-8 IMMUNIC, INC.

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912778.html

Form 8-K IMMUNIC, INC. For: Aug 06

Tue, 11 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901272.html

Form 8-K IMMUNIC, INC. For: Aug 06

Tue, 11 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901272.html

Form 10-Q IMMUNIC, INC. For: Jun 30

Tue, 11 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260811/26900998.html

Form 10-Q IMMUNIC, INC. For: Jun 30

Tue, 11 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260811/26900998.html